Metabolomic analysis of human cirrhosis, hepatocellular carcinoma, non-alcoholic fatty liver disease and non-alcoholic steatohepatitis diseases

Gastroenterology and Hepatology from Bed to Bench

Volumn 9, Issue 3, 2016, Pages 158-173

  Safaei, Akram ^a   Oskouie, Afsaneh Arefi ^b   Mohebbi, Seyed Reza ^b   Rezaei Tavirani, Mostafa ^a   Mahboubi, Mohammad ^c   Peyvandi, Maryam ^a   Okhovatian, Farshad ^b   Zamanian Azodi, Mona ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c ABADAN SCHOOL OF MEDICAL SCIENCES   (Iran)

Author keywords

Cirrhosis; HCC; Metabolomics; NAFLD; NASH

Indexed keywords

BIOLOGICAL MARKER;

AMINO ACID METABOLISM; ARTICLE; CITRIC ACID CYCLE; DISEASE ASSOCIATION; DISEASE COURSE; DOWN REGULATION; FATTY ACID OXIDATION; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER METABOLISM; METABOLITE; METABOLOMICS; NONALCOHOLIC FATTY LIVER; OXIDATIVE STRESS; SIGNAL TRANSDUCTION;

EID: 84976299744     PISSN: 20082258     EISSN: 20084234     Source Type: Journal    
DOI: None     Document Type: Article

References (103)

1. Schuppan D, Afdhal NH. Liver cirrhosis. Lancet 2008; 371: 838-51.
2. Heidelbaugh JJ, Bruderly M. Cirrhosis and chronic liver failure: part I. Diagnosis and evaluation. Am Fam Physician 2006; 74: 756-62.
3. Qi SW, Tu ZG, Peng WJ, Wang LX, Ou-Yang X, Cai AJ, et al. 1H NMR-based serum metabolic profiling in compensated and decompensated cirrhosis. World J Gastroenterol 2012; 18: 285-90.
4. Xue R, Dong L, Wu H, Liu T, Wang J, Shen X. Gas chromatography/mass spectrometry screening of serum metabolomic biomarkers in hepatitis B virus infected cirrhosis patients. Clin Chem Lab Med 2009; 47: 305-10.
5. Gomase VS, Changbhale SS, Patil SA, Kale KV. Metabolomics. Curr Drug Metab 2008; 9: 89-98.
6. Zamanian-Azodi M, Rezaei-Tavirani M, Rahmati-Rad S, Hasanzadeh H, Tavirani MR, Seyyedi SS. Protein-Protein Interaction Network could reveal the relationship between the breast and colon cancer. Gastroenterol Hepatol Bed Bench 2015; 8: 215-24.
7. Zali H, Rezaei-Tavirani M, Azodi M. Gastric cancer: prevention, risk factors and treatment. Gastroenterol Hepatol Bed Bench 2011; 4: 175-85.
8. Zamanian-Azodi M, Rezaei-Tavirani M, Hasanzadeh H, RahmatiRad S, Dalilan S, Gilanchi S, et al. Introducing biomarker panel in esophageal, gastric, and colon cancers; a proteomic approach. Gastroenterol Hepatol Bed Bench 2014; 1: 6-18.
9. Safari-Alighiarloo N, Taghizadeh M, Rezaei-Tavirani M, Goliaei B, Peyvandi AA. Protein-Protein Interaction Networks (PPI) and complex diseases. Gastroenterol Hepatol Bed Bench 2014; 7: 17-31.
10. Safaei A, Tavirani MR, Oskouei AA, Azodi MZ, Mohebbi SR, Nikzamir AR. Protein-protein interaction network analysis of cirrhosis liver disease. Gastroenterol Hepatol Bed Bench 2016; 9: 114-23.
11. Rezaei-Tavirani M, Zamanian-Azodi M, Rajabi S, Masoudi-Nejad A, Rostami-Nejad M, Rahmatirad S. Protein clustering and interactome analysis in Parkinson and Alzheimer's diseases. Arch Iran Med 2016; 19: 101-9.
12. Xue R, Lin Z, Deng C, Dong L, Liu T, Wang J, et al. A serum metabolomic investigation on hepatocellular carcinoma patients by chemical derivatization followed by gas chromatography/mass spectrometry. Rapid Commun Mass Spectrom 2008; 22: 3061-68.
13. Bu Q, Huang Y, Yan G, Cen X, Zhao YL. Metabolomics: a revolution for novel cancer marker identification. Comb Chem High Throughput Screen 2012; 15: 266-75.
14. Wojakowska A, Chekan M, Widlak P, Pietrowska M. Application of metabolomics in thyroid cancer research. Inter J Endocrinol 2015; 2015: 258763.
15. Bro R, Kamstrup-Nielsen MH, Engelsen SB, Savorani F, Rasmussen MA, Hansen L, et al. Forecasting individual breast cancer risk using plasma metabolomics and biocontours. Metabolomics 2015; 11: 1376-80.
16. Fathi F, Ektefa F, Oskouie AA, Rostami K, Rezaei-Tavirani M, Alizadeh AHM, et al. NMR based metabonomics study on celiac disease in the blood serum. Gastroenterol Hepatol Bed Bench 2013; 6: 190-94.
17. Fathi F, Kasmaee LM, Sohrabzadeh K, Rostami-Nejad M, Tafazzoli M, Oskouie AA. The differential diagnosis of Crohn's disease and celiac disease using nuclear magnetic resonance spectroscopy. Appl Magn Reson 2014; 45: 451-59.
18. Fathi F, Majari-Kasmaee L, Mani-Varnosfaderani A, Kyani A, Rostami-Nejad M, Sohrabzadeh K, et al. 1H NMR based metabolic profiling in Crohn's disease by random forest methodology. Magn Reson Chem 2014; 52: 370-76.
19. Fathi F, Oskouie AA, Tafazzoli M, Naderi N, Sohrabzedeh K, Fathi S, et al. Metabonomics based NMR in Crohn's disease applying PLS-DA. Gastroenterol Hepatol Bed Bench 2013; 6: S82-6.
20. Nobakht MGBF, Aliannejad R, Rezaei-Tavirani M, Taheri S, Oskouie AA. The metabolomics of airway diseases, including COPD, asthma and cystic fibrosis. Biomarkers 2015; 20: 5-16.
21. Arakaki AK, Skolnick J, McDonald JF. Marker metabolites can be therapeutic targets as well. Nature 2008; 456: 443.
22. Wang X, Zhang A, Han Y, Wang P, Sun H, Song G, et al. Urine metabolomics analysis for biomarker discovery and detection of jaundice syndrome in patients with liver disease. Mol Cell Proteomics 2012; 11: 370-80.
23. Claudino WM, Quattrone A, Biganzoli L, Pestrin M, Bertini I, Di Leo A. Metabolomics: available results, current research projects in breast cancer, and future applications. J Clin Oncol 2007; 25: 2840-46.
24. Zhang A, Sun H, Yan G, Wang P, Wang X. Mass spectrometry-based metabolomics: applications to biomarker and metabolic pathway research. Biomed Chromatogr 2016; 30: 7-12.
25. Khamis MM, Adamko DJ, El-Aneed A. Mass spectrometric based approaches in urine metabolomics and biomarker discovery. Mass Spectrom Rev 2015; 16: 21455.
26. Dunn WB, Ellis DI. Metabolomics: current analytical platforms and methodologies. Trend Anal Chem 2005; 24: 285-94.
27. Alonso A, Marsal S, Julià A. Analytical methods in untargeted metabolomics: state of the art in 2015. Front Bioeng Biotechnol 2015; 3: 23.
28. Mokdad AA, Lopez AD, Shahraz S, Lozano R, Mokdad AH, Stanaway J, et al. Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis. BMC Med 2014; 18: 145-69.
29. Kim MY, Baik SK. Hyperdynamic circulation in patients with liver cirrhosis and portal hypertension. Korean J Gastroenterol 2009; 54: 143-48.
30. Gao H, Lu Q, Liu X, Cong H, Zhao L, Wang H, et al. Application of 1H NMR-based metabonomics in the study of metabolic profiling of human hepatocellular carcinoma and liver cirrhosis. Can Sci 2009; 100: 782-85.
31. Xue R, Dong L, Wu H, Liu T, Wang J, Shen X. Gas chromatography/mass spectrometry screening of serum metabolomic biomarkers in hepatitis B virus infected cirrhosis patients. Clin Chem Lab Med 2009; 47: 305-10.
32. Fitian AI, Nelson DR, Liu C, Xu Y, Ararat M, Cabrera R. Integrated metabolomic profiling of hepatocellular carcinoma in hepatitis C cirrhosis through GC/MS and UPLC/MS-MS. Liver Int 2014; 34: 1428-44.
33. Yang T, Zheng X, Xing F, Zhuo H, Liu C. Serum metabolomic characteristics of patients with liver cirrhotic ascites. Integr Med Int 2014; 1: 136-43.
34. Lin X, Zhang Y, Ye G, Li X, Yin P, Ruan Q, et al. Classification and differential metabolite discovery of liver diseases based on plasma metabolic profiling and support vector machines. J Sep Sci 2011; 34: 3029-36.
35. Yin P, Wan D, Zhao C, Chen J, Zhao X, Wang W, et al. A metabonomic study of hepatitis B-induced liver cirrhosis and hepatocellular carcinoma by using RP-LC and HILIC coupled with mass spectrometry. Mol Biosyst 2009; 5: 868-76.
36. Shao Y, Zhu B, Zheng R, Zhao X, Yin P, Lu X, et al. Development of urinary pseudo-targeted LC-MS based metabolomics method and its application in hepatocellular carcinoma biomarker discovery. J Proteome Res 2015; 14: 906-16.
37. Dai W, Yin P, Chen P, Kong H, Luo P, Xu Z, et al. Study of urinary steroid hormone disorders: difference between hepatocellular carcinoma in early stage and cirrhosis. Anal Bioanal Chem 2014; 406: 4325-35.
38. Martínez-Granados B, Morales JM, Rodrigo JM, Del Olmo J, Serra MA, Ferrández A, et al. Metabolic profile of chronic liver disease by NMR spectroscopy of human biopsies. Int J Mol Med 2011; 27: 111-17.
39. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-76.
40. Chen F, Xue J, Zhou L, Wu S, Chen Z. Identification of serum biomarkers of hepatocarcinoma through liquid chromatography/mass spectrometry-based metabonomic method. Anal Bioanal Chem 2011; 401: 1899-904.
41. Tan Y, Yin P, Tang L, Xing W, Huang Q, Cao D, et al. Metabolomics study of stepwise hepatocarcinogenesis from the model rats to patients: potential biomarkers effective for small hepatocellular carcinoma diagnosis. Mol Cell Proteomics 2012; 11: 14-9.
42. Yang Y, Li C, Nie X, Feng X, Chen W, Yue Y, et al. Metabonomic studies of human hepatocellular carcinoma using high-resolution magic-angle spinning 1H NMR spectroscopy in conjunction with multivariate data analysis. J Proteome Res 2007; 6: 2605-14.
43. Chen T, Xie G, Wang X, Fan J, Qiu Y, Zheng X, et al. Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma. Mol Cell Proteomics 2011; 10: 25-31.
44. Patterson AD, Maurhofer O, Beyoglu D, Lanz C, Krausz KW, Pabst T, et al. Aberrant lipid metabolism in hepatocellular carcinoma revealed by plasma metabolomics and lipid profiling. Cancer Res 2011; 71: 6590-600.
45. Wang B, Chen D, Chen Y, Hu Z, Cao M, Xie Q, et al. Metabonomic profiles discriminate hepatocellular carcinoma from liver cirrhosis by ultraperformance liquid chromatography-mass spectrometry. J Proteome Res 2012; 11: 1217-27.
46. Ye G, Zhu B, Yao Z, Yin P, Lu X, Kong H, et al. Analysis of urinary metabolic signatures of early hepatocellular carcinoma recurrence after surgical removal using gas chromatography-mass spectrometry. J Proteome Res 2012; 11: 4361-72.
47. Ressom HW, Xiao JF, Tuli L, Varghese RS, Zhou B, Tsai TH, et al. Utilization of metabolomics to identify serum biomarkers for hepatocellular carcinoma in patients with liver cirrhosis. Anal Chim Acta 2012; 743: 90-100.
48. Xiao JF, Varghese RS, Zhou B, Nezami Ranjbar MR, Zhao Y, Tsai TH, et al. LC-MS based serum metabolomics for identification of hepatocellular carcinoma biomarkers in Egyptian cohort. J Proteome Res 2012; 11: 5914-23.
49. Zhang A, Sun H, Yan G, Han Y, Ye Y, Wang X. Urinary metabolic profiling identifies a key role for glycocholic acid in human liver cancer by ultra-performance liquid-chromatography coupled with high-definition mass spectrometry. Clin Chim Acta 2013; 418: 86-90.
50. Nahon P, Amathieu R, Triba MN, Bouchemal N, Nault J-C, Ziol M, et al. Identification of serum proton NMR metabolomic fingerprints associated with hepatocellular carcinoma in patients with alcoholic cirrhosis. Clin Can Res 2012; 18: 6714-22.
51. Chen J, Wang W, Lv S, Yin P, Zhao X, Lu X, et al. Metabonomics study of liver cancer based on ultra performance liquid chromatography coupled to mass spectrometry with HILIC and RPLC separations. Anal Chim Acta 2009; 650: 3-9.
52. Budhu A, Roessler S, Zhao X, Yu Z, Forgues M, Ji J, et al. Integrated metabolite and gene expression profiles identify lipid biomarkers associated with progression of hepatocellular carcinoma and patient outcomes. Gastroenterology 2013; 144: 1066-75.
53. Beyoglu D, Imbeaud S, Maurhofer O, Bioulac-Sage P, Zucman-Rossi J, Dufour JF, et al. Tissue metabolomics of hepatocellular carcinoma: tumor energy metabolism and the role of transcriptomic classification. Hepatology 2013; 58: 229-38.
54. Shariff MI, Gomaa AI, Cox IJ, Patel M, Williams HR, Crossey MM, et al. Urinary metabolic biomarkers of hepatocellular carcinoma in an Egyptian population: a validation study. J Proteome Res 2011; 10: 1828-36.
55. Wu H, Xue R, Dong L, Liu T, Deng C, Zeng H, et al. Metabolomic profiling of human urine in hepatocellular carcinoma patients using gas chromatography/mass spectrometry. Anal Chim Acta 2009; 648: 98-104.
56. Yang J, Xu G, Zheng Y, Kong H, Pang T, Lv S, et al. Diagnosis of liver cancer using HPLC-based metabonomics avoiding false-positive result from hepatitis and hepatocirrhosis diseases. J Chromatogr B Analyt Technol Biomed Life Sci 2004; 813: 59-65.
57. Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology 2009; 49: 306-17.
58. Poynard T, Ratziu V, Naveau S, Thabut D, Charlotte F, Messous D, et al. The diagnostic value of biomarkers (Steatotest) for the prediction of liver steatosis. Comp Hepatol 2005; 4: 10-24.
59. Guha I, Parkes J, Roderick P, Harris S, Rosenberg W. Non-invasive markers associated with liver fibrosis in non-alcoholic fatty liver disease. Gut 2006; 55: 1650-60.
60. Preiss D, Sattar N. Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations. Clin Sci 2008; 115: 141-50.
61. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-31.
62. Adams LA, Angulo P, Lindor KD. Nonalcoholic fatty liver disease. CMAJ 2005; 172: 899-905.
63. Adams LA, Lindor KD. Nonalcoholic fatty liver disease. Ann Epidemiol 2007; 17: 863-69.
64. Kneeman JM, Misdraji J, Corey KE. Secondary causes of nonalcoholic fatty liver disease. Therap Adv Gastroenterol 2012; 5: 199-207.
65. Sakaguchi S, Takahashi S, Sasaki T, Kumagai T, Nagata K. Progression of alcoholic and non-alcoholic steatohepatitis: common metabolic aspects of innate immune system and oxidative stress. Drug Metab Pharmacokinet 2010; 26: 30-46.
66. Liang W, Lindeman JH, Menke AL, Koonen DP, Morrison M, Havekes LM, et al. Metabolically induced liver inflammation leads to NASH and differs from LPS-or IL-1ß-induced chronic inflammation. Lab Invest 2014; 94: 491-502.
67. Puri P, Wiest MM, Cheung O, Mirshahi F, Sargeant C, Min HK, et al. The plasma lipidomic signature of nonalcoholic steatohepatitis. Hepatology 2009; 50: 1827-38.
68. Barr J, Vázquez-Chantada M, Alonso C, Pérez-Cormenzana M, Mayo R, Galán A, et al. Liquid chromatography-mass spectrometry-based parallel metabolic profiling of human and mouse model serum reveals putative biomarkers associated with the progression of nonalcoholic fatty liver disease. J Proteome Res 2010; 9: 4501-12.
69. García-Canaveras JC, Donato MT, Castell JV, Lahoz A. A comprehensive untargeted metabonomic analysis of human steatotic liver tissue by RP and HILIC chromatography coupled to mass spectrometry reveals important metabolic alterations. J Proteome Res 2011; 10: 4825-34.
70. Kalhan SC, Guo L, Edmison J, Dasarathy S, McCullough AJ, Hanson RW, et al. Plasma metabolomic profile in nonalcoholic fatty liver disease. Metabolism 2011; 60: 404-13.
71. Li S, Liu H, Jin Y, Lin S, Cai Z, Jiang Y. Metabolomics study of alcohol-induced liver injury and hepatocellular carcinoma xenografts in mice. J Chromatogr B Analyt Technol Biomed Life Sci 2011; 879: 2369-75.
72. Landel AM, Hammond WG, Meguid MM. Aspects of amino acid and protein metabolism in cancer-bearing states. Cancer 1985; 55: 230-37.
73. O'Connell TM. The complex role of branched chain amino acids in diabetes and cancer. Metabolites 2013; 3: 931-45.
74. Nezami RM, Luo Y, Di Poto C, Varghese R, Ferrarini A, Zhang C, et al. GC-MS based plasma metabolomics for identification of candidate biomarkers for hepatocellular carcinoma in Egyptian Cohort. PLoS One 2014; 10: e0127299.
75. Zhou S, Huang C, Wei Y. The metabolic switch and its regulation in cancer cells. Sci China Life Sci 2010; 53: 942-58.
76. Stirpe F, Ravaioli M, Battelli MG, Musiani S, Grazi GL. Xanthine oxidoreductase activity in human liver disease. Am J Gastroenterol 2002; 97: 2079-85.
77. Chaneton B, Hillmann P, Zheng L, Martin AC, Maddocks OD, Chokkathukalam A, et al. Serine is a natural ligand and allosteric activator of pyruvate kinase M2. Nature 2012; 491: 458-62.
78. Yabu M, Shime H, Hara H, Saito T, Matsumoto M, Seya T, et al. IL-23-dependent and -independent enhancement pathways of IL-17A production by lactic acid. Int Immunol 2011; 23: 29-41.
79. Goetze K, Walenta S, Ksiazkiewicz M, Kunz-Schughart LA, Mueller-Klieser W. Lactate enhances motility of tumor cells and inhibits monocyte migration and cytokine release. Int J Oncol 2011; 39: 453-63.
80. Bradbury MJ, Campbell U, Giracello D, Chapman D, King C, Tehrani L. Metabotropic glutamate receptor mGlu5 is a mediator of appetite and energy balance in rats and mice. J Pharmacol Exp Ther 2005; 313: 395-402.
81. Prickett TD, Samuels Y. Molecular pathways: dysregulated glutamatergic signaling pathways in cancer. Clin Cancer Res 2012; 18: 4240-46.
82. Amodio P, Angeli P, Merkel C, Menon F, Gatta A. Plasma carnitine levels in liver cirrhosis: relationship with nutritional status and liver damage. Clin Chem Lab Med 1990; 28: 619-26.
83. de la Peña CA, Rozas I, Alvarez-Prechous A, Pardinas M, Paz J, Rodriguez-Segade S. Free carnitine and acylcarnitine levels in sera of alcoholics. Biochem Med Metab Biol 1990; 44: 77-83.
84. Cao H, Huang H, Xu W, Chen D, Yu J, Li J, et al. Fecal metabolome profiling of liver cirrhosis and hepatocellular carcinoma patients by ultra performance liquid chromatography-mass spectrometry. Anal Chim Acta 2011; 691: 68-75.
85. Wu JM, Skill NJ, Maluccio MA. Evidence of aberrant lipid metabolism in hepatitis C and hepatocellular carcinoma. HPB 2010; 12: 625-36.
86. Uderhardt S, Krönke G. 12/15-Lipoxygenase during the regulation of inflammation, immunity, and self-tolerance. J Mol Med 2012; 90: 1247-56.
87. Liu B, Timar J, Howlett J, Diglio C, Honn K. Lipoxygenase metabolites of arachidonic and linoleic acids modulate the adhesion of tumor cells to endothelium via regulation of protein kinase C. Cell Regul 1991; 2: 1045-55.
88. Ma J, Zhang L, Zhang J, Liu M, Wei L, Shen T, et al. 15-Lipoxygenase-1/15-hydroxyeicosatetraenoic acid promotes hepatocellular cancer cells growth through protein kinase B and heat shock protein 90 complex activation. Int J Biochem Cell Biol 2013; 45: 1031-41.
89. Hosoi T, Koguchi Y, Sugikawa E, Chikada A, Ogawa K, Tsuda N, et al. Identification of a novel human eicosanoid receptor coupled to Gi/o. J Biol Chem 2002; 277: 31459-65.
90. Dorsam RT, Gutkind JS. G-protein-coupled receptors and cancer. Nat Rev Cancer 2007; 7: 79-94.
91. Yan M, Li H, Zhu M, Zhao F, Zhang L, Chen T, et al. G protein-coupled receptor 87 (GPR87) promotes the growth and metastasis of CD133+ cancer stem-like cells in hepatocellular carcinoma. PLoS One 2013; 8: e61056.
92. Marra M, Sordelli IM, Lombardi A, Lamberti M, Tarantino L, Giudice A, et al. Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: an overview. J Transl Med 2011; 9: 1479-5876.
93. Constantinou MA, Theocharis SE, Mikros E. Application of metabonomics on an experimental model of fibrosis and cirrhosis induced by thioacetamide in rats. Toxicol Appl Pharm 2007; 218: 11-9.
94. Barber MN, Risis S, Yang C, Meikle PJ, Staples M, Febbraio MA, et al. Plasma lysophosphatidylcholine levels are reduced in obesity and type 2 diabetes. PLoS One 2012; 7: e41456.
95. Goetzl EJ. Pleiotypic mechanisms of cellular responses to biologically active lysophospholipids. Prostaglandins Other Lipid Mediat 2001; 64: 11-20.
96. Kita T, Kume N, Ishii K, Horiuchi H, Arai H, Yokode M. Oxidized LDL and expression of monocyte adhesion molecules. Diabetes Res Clin 1999; 45: 123-26.
97. Barnes S, Gallo GA, Trash DB, Morris JS. Diagnositic value of serum bile acid estimations in liver disease. J Clin Pathol 1975; 28: 506-9.
98. Neale G, Lewis B, Weaver V, Panveliwalla D. Serum bile acids in liver disease. Gut 1971; 12: 145-52.
99. Festi D, Labate AMM, Roda A, Bazzoli F, Frabboni R, Rucci P, et al. Diagnostic effectiveness of serum bile acids in liver diseases as evaluated by multivariate statistical methods. Hepatology 1983; 3: 707-13.
100. Gowda GN. Human bile as a rich source of biomarkers for hepatopancreatobiliary cancers. Biomarkers Med 2010; 4: 299-314.
101. Maruyama T, Miyamoto Y, Nakamura T, Tamai Y, Okada H, Sugiyama E, et al. Identification of membrane-type receptor for bile acids (M-BAR). Biochem Biophys Res Commun 2002; 298: 714-19.
102. Thomas C, Pellicciari R, Pruzanski M, Auwerx J, Schoonjans K. Targeting bile-acid signaling for metabolic diseases. Nat Rev Drug Discov 2008; 7: 678-93.
103. Watanabe M, Houten SM, Mataki C, Christoffolete MA, Kim BW, Sato H, et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 2006; 439: 484-89.